CASI Pharmaceuticals, Inc. has appointed Daniel Lang, MD as Chief Financial Officer and Senior Vice President.
Dr. Lang has more than 30 years of experience as a physician-scientist, investor, and biotech executive. He is a cardiologist by training from UCSF, followed by 20 years of investment experience as a portfolio manager at Farallon Capital and Chief Investment Officer at RS Investments Value Group.
Most recently, he was the President of Athenex cell therapy division and led clinical development of the NKT cell platform.
"We are delighted to have Dan join us at this exciting time at CASI. His unique combination of clinical, operational and capital market experience will contribute to the strategic pivot of the anti-CD38 program to focus on antibody-mediated rejection (AMR) and Idiopathic thrombocytopenia purpura (ITP)," said Dr. Wei-Wu He, Chairman and CEO of CASI Pharmaceuticals.
Dr. Lang commented, "I am excited to join CASI to execute the Company's strategy in maximizing the value of its pipeline products, especially CID-103 which has a great potential to address unmet medical needs for autoimmune disease patients."
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and worldwide. The company is focused on acquiring, developing, and commercializing products that augment its hematology-oncology therapeutic focus and other areas of unmet medical need.
The company intends to execute its plan to become a leader by launching medicines in the Greater China market, leveraging the company's China-based regulatory and commercial competencies and its global drug development expertise. The company's operations in China are conducted through its wholly owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy